Prognostic significance of plasma cytomegalovirus (CMV) DNA load in immunocompetent patients with CMV pneumonia: A retrospective cohort study

IF 6.8 3区 医学 Q1 VIROLOGY Journal of Medical Virology Pub Date : 2024-10-21 DOI:10.1002/jmv.70019
Özge Aydın Güçlü, Ezgi Demirdöğen, Esra Kazak, Nilüfer Aylin Acet Öztürk, Merve Nur Yıldız, Orkun Eray Terzi, Aslı Görek Dilektaşlı, Ahmet Ursavaş
{"title":"Prognostic significance of plasma cytomegalovirus (CMV) DNA load in immunocompetent patients with CMV pneumonia: A retrospective cohort study","authors":"Özge Aydın Güçlü,&nbsp;Ezgi Demirdöğen,&nbsp;Esra Kazak,&nbsp;Nilüfer Aylin Acet Öztürk,&nbsp;Merve Nur Yıldız,&nbsp;Orkun Eray Terzi,&nbsp;Aslı Görek Dilektaşlı,&nbsp;Ahmet Ursavaş","doi":"10.1002/jmv.70019","DOIUrl":null,"url":null,"abstract":"<p>Cytomegalovirus (CMV) pneumonia, often presented as pneumonitis, is characterized by respiratory failure and large interstitial infiltrates visible on chest radiographs. This retrospective cohort study investigates the predictive significance of plasma CMV DNA load on the short- and long-term mortality among immunocompetent patients diagnosed with CMV pneumonia. The study included 61 immunocompetent patients suspected of having CMV pneumonia, treated with intravenous ganciclovir after positive CMV DNA results from bronchoalveolar lavage or plasma. Our multivariate Cox regression analysis identified several independent predictors of mortality. Having idiopathic pulmonary fibrosis (IPF) significantly increased the risk of in-hospital mortality (HR: 7.27, 95% CI: 1.62–32.52, <i>p</i> = 0.009), as did shorter durations of antiviral therapy (HR: 0.90, 95% CI: 0.84–0.97, <i>p</i> = 0.005) and higher CMV DNA levels (&gt;3870 IU/mL; HR: 9.63, 95% CI: 2.32–39.98, <i>p</i> = 0.002). High CMV DNA levels (&gt;5154 IU/mL) were also predictors of 30-day mortality (HR: 9.39, 95% CI: 2.20–40.01, <i>p</i> = 0.002). For 1-year mortality, the presence of IPF (HR: 2.96, 95% CI: 1.08–8.06, <i>p</i> = 0.034), hypersensitivity pneumonia (HP) (HR: 4.30, 95% CI: 1.57–11.78, <i>p</i> = 0.005), shorter duration of total antiviral therapy (HR: 0.95, 95% CI: 0.93–0.99, <i>p</i> = 0.010), and higher CMV DNA levels (&gt;327 IU/mL) (HR: 3.36, 95% CI: 1.33–8.47, <i>p</i> = 0.010) were identified as independent determinants. The study reveals that IPF increases short and long-term mortality risks, while HP increases long-term mortality. Extended antiviral treatment duration results in a 10% reduction in in-hospital mortality for each additional day of treatment. Furthermore, elevated viral loads are associated with higher mortality rates, highlighting the necessity for careful monitoring.</p>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":"96 10","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.70019","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Virology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jmv.70019","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Cytomegalovirus (CMV) pneumonia, often presented as pneumonitis, is characterized by respiratory failure and large interstitial infiltrates visible on chest radiographs. This retrospective cohort study investigates the predictive significance of plasma CMV DNA load on the short- and long-term mortality among immunocompetent patients diagnosed with CMV pneumonia. The study included 61 immunocompetent patients suspected of having CMV pneumonia, treated with intravenous ganciclovir after positive CMV DNA results from bronchoalveolar lavage or plasma. Our multivariate Cox regression analysis identified several independent predictors of mortality. Having idiopathic pulmonary fibrosis (IPF) significantly increased the risk of in-hospital mortality (HR: 7.27, 95% CI: 1.62–32.52, p = 0.009), as did shorter durations of antiviral therapy (HR: 0.90, 95% CI: 0.84–0.97, p = 0.005) and higher CMV DNA levels (>3870 IU/mL; HR: 9.63, 95% CI: 2.32–39.98, p = 0.002). High CMV DNA levels (>5154 IU/mL) were also predictors of 30-day mortality (HR: 9.39, 95% CI: 2.20–40.01, p = 0.002). For 1-year mortality, the presence of IPF (HR: 2.96, 95% CI: 1.08–8.06, p = 0.034), hypersensitivity pneumonia (HP) (HR: 4.30, 95% CI: 1.57–11.78, p = 0.005), shorter duration of total antiviral therapy (HR: 0.95, 95% CI: 0.93–0.99, p = 0.010), and higher CMV DNA levels (>327 IU/mL) (HR: 3.36, 95% CI: 1.33–8.47, p = 0.010) were identified as independent determinants. The study reveals that IPF increases short and long-term mortality risks, while HP increases long-term mortality. Extended antiviral treatment duration results in a 10% reduction in in-hospital mortality for each additional day of treatment. Furthermore, elevated viral loads are associated with higher mortality rates, highlighting the necessity for careful monitoring.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
免疫功能正常的 CMV 肺炎患者血浆巨细胞病毒 (CMV) DNA 负载的预后意义:一项回顾性队列研究
巨细胞病毒(CMV)肺炎通常表现为肺炎,其特点是呼吸衰竭和胸片可见大面积间质浸润。这项回顾性队列研究探讨了血浆 CMV DNA 负荷对确诊为 CMV 肺炎的免疫功能正常患者短期和长期死亡率的预测意义。研究纳入了 61 名疑似 CMV 肺炎的免疫功能正常患者,他们在支气管肺泡灌洗液或血浆中 CMV DNA 检测结果呈阳性后接受了静脉注射更昔洛韦治疗。我们的多变量 Cox 回归分析确定了几个独立的死亡率预测因素。特发性肺纤维化(IPF)会显著增加院内死亡风险(HR:7.27,95% CI:1.62-32.52,p = 0.009),抗病毒治疗持续时间较短(HR:0.90,95% CI:0.84-0.97,p = 0.005)和 CMV DNA 水平较高(3870 IU/mL;HR:9.63,95% CI:2.32-39.98,p = 0.002)也会增加院内死亡风险。高 CMV DNA 水平(>5154 IU/mL)也是 30 天死亡率的预测因素(HR:9.39,95% CI:2.20-40.01,p = 0.002)。就 1 年死亡率而言,存在 IPF(HR:2.96,95% CI:1.08-8.06,p = 0.034)、超敏性肺炎(HP)(HR:4.30,95% CI:1.57-11.78,p = 0.005)、总抗病毒治疗时间较短(HR:0.95,95% CI:0.93-0.99,p = 0.010)和较高的 CMV DNA 水平(>327 IU/mL)(HR:3.36,95% CI:1.33-8.47,p = 0.010)被确定为独立决定因素。研究显示,IPF 会增加短期和长期死亡风险,而 HP 会增加长期死亡率。延长抗病毒治疗时间每增加一天,院内死亡率就会降低 10%。此外,病毒载量的升高与较高的死亡率有关,这突出了仔细监测的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Medical Virology
Journal of Medical Virology 医学-病毒学
CiteScore
23.20
自引率
2.40%
发文量
777
审稿时长
1 months
期刊介绍: The Journal of Medical Virology focuses on publishing original scientific papers on both basic and applied research related to viruses that affect humans. The journal publishes reports covering a wide range of topics, including the characterization, diagnosis, epidemiology, immunology, and pathogenesis of human virus infections. It also includes studies on virus morphology, genetics, replication, and interactions with host cells. The intended readership of the journal includes virologists, microbiologists, immunologists, infectious disease specialists, diagnostic laboratory technologists, epidemiologists, hematologists, and cell biologists. The Journal of Medical Virology is indexed and abstracted in various databases, including Abstracts in Anthropology (Sage), CABI, AgBiotech News & Information, National Agricultural Library, Biological Abstracts, Embase, Global Health, Web of Science, Veterinary Bulletin, and others.
期刊最新文献
Concerns on a New Varicella Vaccine Introduced in Korea Molecular Analysis of Coxsackievirus B2 Associated With Severe Symptoms of the Central Nervous System Rhinovirus in pediatric respiratory infections: More than a simple cold Epidemiological Characteristics of Neuro-Specific Antibodies Following Viral Infections Identifying Gaps in Congenital CMV Detection—Implications for the Recent European Consensus Guidelines on Congenital CMV Infection
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1